Optimal timing of Danhong injection for the prevention of microvascular obstruction in ST-elevation myocardial infarction: Danhong Injection before or after percutaneous coronary intervention trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021440

Enrollment

Unknown

Registered

2019-02-21

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-elevation myocardial infarction

Interventions

control group:routine treatments and PCI

preoperative-Danhong group:routine treatments plus Danhong injection treatment started before PCI

postoperative-Danhong group:routine treatmentst plus Danhong injection treatment started after PCI

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of ST-segment elevation myocardial infarction; 2. Show the symptoms of myocardial ischemia within 12 hours; 3. Have direct PCI surgery indications and accept stent placement in infarct vessels; 4. Men and women aged between 18-75 years; 5. Agree to participate the research and sign the Informed Consent Form.

Exclusion criteria

Exclusion criteria: 1. Received thrombolytic therapy before PCI; 2. Cardiogenic shock, heart rupture or ventricular septal perforation; 3. Cardiopulmonary resuscitation ? 20 minutes; 4. Active hemorrhage or sensitive to hemorrhage; 5. Target vessel received stent implantation; 6. With an implantable cardiac defibrillator or pacemaker; 7. Combined with severe liver, kidney or hematopoietic system diseases, malignant tumors; 8. Allergic to the experimental drugs; 9. Patients with major mental illnesses that are difficult to cooperate; 10. Known pregnancy or lactation; 11. Acute pericarditis, subacute infective endocarditis and/or aortic dissection; 12. Left bundle branch block; 13. Life expectancy=12 months; 14. Participation in another clinical study with an investigational product or device study during the last 30 days or during the study.

Design outcomes

Primary

Measure	Time frame
STR;	—

Secondary

Measure	Time frame
ST-segment elevation;TIMI;TMPG;LVEF;cTnI AUC;CK-MB AUC;NT-proBNP;hs-CRP;MACE;readmission for heart failure or angina pectoris;SF-12;	—

Countries

China

Contacts

Public ContactHongcai Shang, Lijing Zhang

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

shanghongcai@126.com+86 010 84012510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026